File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis

TitleCommunity-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis
Authors
KeywordsAnemia
Cost-effectiveness
Maternal mortality
Misoprostol
Postpartum hemorrhage
Issue Date2010
Citation
International Journal of Gynecology and Obstetrics, 2010, v. 108, n. 3, p. 289-294 How to Cite?
AbstractObjective: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). Methods: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10 000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800 μg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600 μg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. Results: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. Conclusion: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY). © 2009 International Federation of Gynecology and Obstetrics.
Persistent Identifierhttp://hdl.handle.net/10722/326797
ISSN
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 0.951
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSutherland, Tori-
dc.contributor.authorMeyer, Carinne-
dc.contributor.authorBishai, David M.-
dc.contributor.authorGeller, Stacie-
dc.contributor.authorMiller, Suellen-
dc.date.accessioned2023-03-31T05:26:34Z-
dc.date.available2023-03-31T05:26:34Z-
dc.date.issued2010-
dc.identifier.citationInternational Journal of Gynecology and Obstetrics, 2010, v. 108, n. 3, p. 289-294-
dc.identifier.issn0020-7292-
dc.identifier.urihttp://hdl.handle.net/10722/326797-
dc.description.abstractObjective: To compare the cost-effectiveness of community-based distribution of misoprostol for prevention with misoprostol for treatment of postpartum hemorrhage (PPH). Methods: A Monte Carlo simulation depicted mortality and anemia-related morbidity attributable to PPH among 3 scenarios of 10 000 women delivering at home in rural India: (1) standard management; (2) standard management plus 800 μg of sublingual misoprostol for PPH treatment; and (3) standard management plus 600 μg of prophylactic oral misoprostol. The model included costs of drugs, birth attendant training, and transport for women who did not respond to misoprostol. Results: Misoprostol lowered mortality by 70% and 81% in scenarios 2 and 3, respectively. Scenarios 2 and 3 raise costs by 6% and 35%, respectively. Incremental cost per disability-adjusted life year (DALY) saved is estimated at $6 and $170, respectively. Conclusion: Both interventions were more effective at decreasing mortality and anemia than standard management. The most efficient scale-up plan would focus initially on increasing coverage with the treatment strategy ($6 per DALY). © 2009 International Federation of Gynecology and Obstetrics.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Gynecology and Obstetrics-
dc.subjectAnemia-
dc.subjectCost-effectiveness-
dc.subjectMaternal mortality-
dc.subjectMisoprostol-
dc.subjectPostpartum hemorrhage-
dc.titleCommunity-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijgo.2009.11.007-
dc.identifier.scopuseid_2-s2.0-76049110718-
dc.identifier.volume108-
dc.identifier.issue3-
dc.identifier.spage289-
dc.identifier.epage294-
dc.identifier.isiWOS:000275615000030-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats